Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: Case series of 36 patients

Radiology

Volumn 253, Issue 1, 2009, Pages 81-89

  Abujudeh, Hani H ^a   Kaewlai, Rathachai ^a   Kagan, Anna ^b   Chibnik, Lori B ^c   Nazarian, Rosalynn M ^a   High, Whitney A ^d   Kay, Jonathan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIAGNOSTIC IMAGING; DIALYSIS; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HEAD; HEART; HUMAN; HYPERTENSION; INSTRUMENT; KAPLAN MEIER METHOD; KIDNEY; KIDNEY ANGIOGRAPHY; LEG; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT; PELVIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SKIN BIOPSY; SPINE; SURVIVAL RATE; SYMPTOM; BIOPSY; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; HOSPITALIZATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 70350507342     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2531082160     Document Type: Article

References (41)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients [letter]. Lancet 2000;356:1000-1001.
2. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003;139:928-930.
3. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-393.
4. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003;114:563-572.
5. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003;139:903-906.
6. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of in-flammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660-2666.
7. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569-577.
8. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005;46:754-759.
9. Cowper SE. Nephrogenic systemic fibrosis: an overview. J Am Coll Radiol 2008;5:23-28.
10. Girardi M. Nephrogenic systemic fibrosis: a dermatologist's perspective. J Am Coll Radiol 2008;5:40-44.
11. Kay J, Bazari H, Avery LL, Koreishi AF. A 46-year-old woman with renal failure and stiffness of the joints and skin, case 6-2008. N Engl J Med 2008;358:827-838.
12. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007;56:3433-3441.
13. Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med 2008;75:112, 114, 117.
14. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
15. Kallen AJ, Jhung MA, Cheng S, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966-975.
16. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
17. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-157.
18. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008;248:799-806.
19. Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol 2008;190:1060-1068.
20. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
21. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-26.
22. Swaminathan S, High WA, Ranville J, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008;73:1413-1418.
23. Khurana A, Greene JFJ, High WA. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008;59:218-224.
24. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18:2164-2173.
25. United States Food and Drug Administration. Information on gadolinium-containing contrast agents. http://www.fda.gov/cder/drug/infopage/ gcca/default.htm. Published June 8, 2006. Updated May 23, 2007. Accessed September 17, 2008.
26. Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007;188:1447-1474.
27. Thomsen HS. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 2007;17:70-76.
28. Kuo PH. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. J Am Coll Radiol 2008;5:29-35.
29. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent "activates" fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214:584-593.
30. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-3178.
31. Marckmann P, Skov L, Rossen K, Thomsen HS. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 2008;69:161-168.
32. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141-144.
33. Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR Am J Roentgenol 2008;190:1069-1075.
34. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 2008;190:736-741.
35. Bayer Healthcare. Magnevist safety information: nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF/NFD). http://www.berleximaging. com/html/magnevist/nsf-nfd.html. Published April 17, 2008. Accessed September 17, 2008.
36. Swaminathan S, Horn TD, Pellowski D, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007;357:720-722.
37. Idée JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-576.
38. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008;3:747-751.
39. United States Food and Drug Administration. MedWatch. http://www.fda.gov/Medwatch/SAFETY/2007/safety07.htm# Gadolinium. Published September 28, 2007. Accessed September 17, 2008.
40. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248:807-816.
41. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004;39:138-142.